Was similar for MI and augmented for stroke and cardiovascular death

Was similar for MI and augmented for stroke and Dimethylenastron site cardiovascular death in CD patients as KS 176 manufacturer compared to UC patients (MI: RR 1.35 [1.03?.77] vs. 1.17 [1.03?.33] p = 0.81, stroke: RR 1.37 [1.10?.72] vs. 1.10 [1.02?.19] p = 0.02 and cardiovascular death: RR 1.63 [1.36?.95] vs. 1.25 [1.14?.37] p = 0.04). In IBD activity analyses without corticosteroid prescriptions as activity marker, we found that the higher cardiovascular risk in periods of IBD disease activity persisted (not shown). When we 1655472 removed hospitalization 25033180 from our IBD disease activity definition, we found similar risks of MI (RR 1.43 [1.09?.87] vs. 1.49 [1.16?.93]) and stroke (RR 1.46 [1.15?.86] vs. 1.53 [1.22?1.92]) during flares. Additionally we compared the risk 120 days after surgery due to pancolitis (K51.0) and proctitis (K51.2) in UC patients, and surgery for isolated colon disease (K50.1) versus morewidespread CD disease (K50.8) in CD patients, respectively. In general, we found elevated risks during this period (all RRs .2) but due to low number of events no significant differences were found between the aforementioned groups (not shown). When we reduced flare length to 60 days, the risk for the composite endpoint in periods with persistent activity was RR 2.67 (2.25?.18) and during flares RR 2.08 (1.82?.37). Also, when flare duration was increased to 180 days the corresponding RR was 1.92 (1.68?.20) in periods with persistent activity and RR 1.75 (1.57?.98) during flares. We identified 679 (3.3 ) patients who received anti-TNF agents in the period from inclusion to end of study. These patients were younger (median [IQR] age 27.6 [20.7?7.6] years) and had shorter (median 1.2 years) follow up time than the general IBD cohort. We found no cardiovascular events among the patients treated with anti-TNF agents within the study period. In total 6,017 patients (28.9 ) who received treatment with 6mercaptopurine, azathioprine and/or methotrexate. In these subjects, we found no significant differences on the risks of MI, stroke and cardiovascular death as compared to the total IBD population (MI: RR 1.15 vs. 1.17 p = 0.88, stroke RR 1.16 vs. 1.14 p = 0.79 and cardiovascular death RR: 1.23 vs. 1.35 p = 0.33). In a sensitivity analysis where we excluded patients with COPD, we found the overall risks of the cardiovascular endpoints for IBD patients essentially unchanged (MI: RR 1.16 [1.03?.32] vs. 1.18 [1.05?.31]], stroke: RR 1.15 [1.04?.27] vs.Figure 3. Risk of myocardial infarction, stroke and cardiovascular death stratified by inflammatory bowel disease activity. CI: confidence interval. RR: Rate ratio. doi:10.1371/journal.pone.0056944.gActive IBD and Risk of Atherothrombotic DiseaseTable 3. Number of events, incidence rates per 1000 person-years, adjusted rate ratios (RRs) and 95 confidence intervals (CIs).Incidence rate Number of events (unadjusted) Myocardial infarction Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls Stroke Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls Cardiovascular death Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls Composite endpoint Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls 869 229 138 1,236 1,155 266 205 765 8,056 10.99 8.18 8.18 9.97 24.87 19.41 33.67 7.35 6.60 540 148 90 77.Was similar for MI and augmented for stroke and cardiovascular death in CD patients as compared to UC patients (MI: RR 1.35 [1.03?.77] vs. 1.17 [1.03?.33] p = 0.81, stroke: RR 1.37 [1.10?.72] vs. 1.10 [1.02?.19] p = 0.02 and cardiovascular death: RR 1.63 [1.36?.95] vs. 1.25 [1.14?.37] p = 0.04). In IBD activity analyses without corticosteroid prescriptions as activity marker, we found that the higher cardiovascular risk in periods of IBD disease activity persisted (not shown). When we 1655472 removed hospitalization 25033180 from our IBD disease activity definition, we found similar risks of MI (RR 1.43 [1.09?.87] vs. 1.49 [1.16?.93]) and stroke (RR 1.46 [1.15?.86] vs. 1.53 [1.22?1.92]) during flares. Additionally we compared the risk 120 days after surgery due to pancolitis (K51.0) and proctitis (K51.2) in UC patients, and surgery for isolated colon disease (K50.1) versus morewidespread CD disease (K50.8) in CD patients, respectively. In general, we found elevated risks during this period (all RRs .2) but due to low number of events no significant differences were found between the aforementioned groups (not shown). When we reduced flare length to 60 days, the risk for the composite endpoint in periods with persistent activity was RR 2.67 (2.25?.18) and during flares RR 2.08 (1.82?.37). Also, when flare duration was increased to 180 days the corresponding RR was 1.92 (1.68?.20) in periods with persistent activity and RR 1.75 (1.57?.98) during flares. We identified 679 (3.3 ) patients who received anti-TNF agents in the period from inclusion to end of study. These patients were younger (median [IQR] age 27.6 [20.7?7.6] years) and had shorter (median 1.2 years) follow up time than the general IBD cohort. We found no cardiovascular events among the patients treated with anti-TNF agents within the study period. In total 6,017 patients (28.9 ) who received treatment with 6mercaptopurine, azathioprine and/or methotrexate. In these subjects, we found no significant differences on the risks of MI, stroke and cardiovascular death as compared to the total IBD population (MI: RR 1.15 vs. 1.17 p = 0.88, stroke RR 1.16 vs. 1.14 p = 0.79 and cardiovascular death RR: 1.23 vs. 1.35 p = 0.33). In a sensitivity analysis where we excluded patients with COPD, we found the overall risks of the cardiovascular endpoints for IBD patients essentially unchanged (MI: RR 1.16 [1.03?.32] vs. 1.18 [1.05?.31]], stroke: RR 1.15 [1.04?.27] vs.Figure 3. Risk of myocardial infarction, stroke and cardiovascular death stratified by inflammatory bowel disease activity. CI: confidence interval. RR: Rate ratio. doi:10.1371/journal.pone.0056944.gActive IBD and Risk of Atherothrombotic DiseaseTable 3. Number of events, incidence rates per 1000 person-years, adjusted rate ratios (RRs) and 95 confidence intervals (CIs).Incidence rate Number of events (unadjusted) Myocardial infarction Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls Stroke Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls Cardiovascular death Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls Composite endpoint Ulcerative colitis Crohns disease Unspecific IBD IBD total Age.45 years Flare Persistent activity Remission Controls 869 229 138 1,236 1,155 266 205 765 8,056 10.99 8.18 8.18 9.97 24.87 19.41 33.67 7.35 6.60 540 148 90 77.

Leave a Reply